Investigational New Drugs ( IF 3.0 ) Pub Date : 2023-04-05 , DOI: 10.1007/s10637-023-01352-9 Antoine Chartouni 1 , Antoine Mouawad 1 , Marc Boutros 1 , Fouad Attieh 1 , Nicolas Medawar 1 , Hampig Raphaël Kourie 1, 2
|
Glioblastoma multiforme (GBM) is the most common and lethal primary tumor of the central nervous system. What makes it so dreadful is the very low survival rate, despite the existence of a standard treatment plan. An innovative and more effective way to treat glioblastoma based on Mesenchymal Stem Cells (MSCs) has been explored recently. MSCs are a group of endogenous multipotent stem cells that could mainly be harvested from adipose tissue, bone marrow, and umbilical cord. Having the ability to migrate toward the tumor using multiple types of binding receptors, they could be used either as a direct treatment (whether they are enhanced or not) or as a delivery vehicle carrying various anti-tumoral agents. Some of these agents are: chemotherapy drugs, prodrug activating therapy, oncolytic viruses, nanoparticles, human artificial chromosome… Promising results have started to surface; however, more evidence is needed to perfect their use as a glioblastoma multiforme treatment option.
Graphical Abstract
Alternative treatment, using unloaded or loaded MSCs, leading to a better outcome
中文翻译：
间充质干细胞：治疗胶质母细胞瘤的特洛伊木马
多形性胶质母细胞瘤 (GBM) 是中枢神经系统最常见和致命的原发性肿瘤。可怕的是，尽管有标准的治疗方案，但存活率非常低。最近探索了一种基于间充质干细胞 (MSC) 治疗胶质母细胞瘤的创新且更有效的方法。MSC 是一组内源性多能干细胞，主要可从脂肪组织、骨髓和脐带中提取。具有使用多种类型的结合受体向肿瘤迁移的能力，它们可以用作直接治疗（无论它们是否增强）或用作携带各种抗肿瘤剂的递送载体。其中一些药物是：化疗药物、前体药物激活疗法、溶瘤病毒、纳米颗粒、人类人工染色体……有希望的结果已经开始浮出水面；然而，需要更多证据来完善它们作为多形性胶质母细胞瘤治疗选择的用途。
图形概要
替代治疗，使用卸载或加载的 MSCs，导致更好的结果
京公网安备 11010802027423号